00:42:01 Europe / Stockholm
Svenska | English

Västra Hamnen Market Focus

Prenumeration

Xintela: Closing in on the first license agreement
2024-05-29 09:45:00

• Non-binding term sheet with EQGen Biomedical regarding EQSTEM
• The financial situation is still an issue
• We keep the fair value at SEK 1.30 per share

In connection with the Q1 report, Xintela announced a signed, non-binding term sheet with the US firm EQGen Biomedical regarding EQSTEM, Xintela’s veterinarian joint disease treatment. We expect details to be disclosed once EQGen Biomedical secures funding and the parties announce a license agreement.

We therefore maintain our risk-adjusted motivated value of SEK 1.30 per share. The full report is available here.

About Market Focus

The research report is prepared as part of Market Focus, Västra Hamnen Corporate Finance's commissioned research offering.

This is a press release from Västra Hamnen Corporate Finance AB. 
Web: vhcorp.se
Twitter: @vhcorp_se (https://twitter.com/vhcorp_se)

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden